Aigner M, Feulner J, Schaffer S et al (2013) T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 27:1107–1115

Article  CAS  PubMed  Google Scholar 

Krupka C, Kufer P, Kischel R et al (2014) CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 123(3):356–365

Article  CAS  PubMed  Google Scholar 

Krupka C, Kufer P, Kischel R et al (2016) Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330. Leukemia 30:484–491

Article  CAS  PubMed  Google Scholar 

Ravandi F, Subklewe M, Walter RB et al (2024) Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study. Leuk Lymphoma 65(9):1281–1291. https://doi.org/10.1080/10428194.2024.2346755

Article  CAS  PubMed  Google Scholar 

Subklewe M et al (2019) Preliminary results from a Phase 1 first-in-human study of AMG 673. Blood 134(Suppl 1):833

Article  Google Scholar 

Narayan R et al (2024) First-in-human study of JNJ-67571244, a CD33\(\times \)CD3 bispecific antibody. Clin Transl Sci 17(3):e13742

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jitschin R, Saul D, Braun M et al (2018) CD33/CD3-bispecific T-cell engaging antibody construct targets myeloid-derived suppressor cells. J Immunother Cancer 6:116

Article  PubMed  PubMed Central  Google Scholar 

Friedrich M, Henn A, Raum T et al (2014) Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther 13(6):1549–1557

Article  CAS  PubMed  Google Scholar 

Harrington KH, Gudgeon CJ, Laszlo GS et al (2015) Preclinical evaluation of the anti-CD33 BiTE AMG 330 in primary AML samples. PLoS ONE 10(3):e0120721

Google Scholar 

Jilani I, Estey E, Huh Y et al (2002) Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 118:560–566

Article  PubMed  Google Scholar 

De Propris MS, Raponi S, Diverio D et al (2011) High CD33 expression levels in AML carrying the NPM1 mutation. Haematologica 96(10):1548–1551

Article  PubMed  PubMed Central  Google Scholar 

Laszlo GS, Gudgeon CJ, Harrington KH et al (2014) Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager antibody, AMG 330, against human AML. Blood 123(4):554–561

Article  CAS  PubMed  Google Scholar 

Eissenberg LG et al (2024) Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564. PLoS ONE 19(3):e0300174

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rettig MP et al (2018) A CiTE targeting CD33 and PD-1. Blood 132:4060. [ASH abstract.]

Linder K et al (2025) STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia. Blood 145(19):2149–2160

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pillarisetti K, Powers G, Luistro L et al (2020) Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv 4(18):4538–4549

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes-Selva D, Perova T, Skerget S et al (2024) Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study. Blood 144(6):615–628

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mhibik M, Gaglione EM, Eik D et al (2023) Cytotoxicity of the CD3\(\times \)CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Adv 7(15):4089–4101

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Horst HJ, de Jonge AV, Hiemstra IH et al (2021) Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J 11:38

Article  PubMed  PubMed Central  Google Scholar 

Agarwal SK, Bhagwat S, Mehta K et al (2020) Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed/refractory AML. J Clin Oncol 38(15 suppl):7536

Article  Google Scholar 

Bellout H, Li A, Piatkov K, Bottino D (2026) A generalization of the ternary binding model to membrane-confined systems with finite copy number. https://doi.org/10.64898/2026.04.10.717668.